Anticoagulation Therapy in Cerebral Venous Thrombosis

Initial Treatment and Duration

All patients with cerebral venous thrombosis require a minimum of 3 months of therapeutic anticoagulation to prevent thrombus extension and early recurrence, regardless of the anticoagulant chosen, as recommended by the American College of Chest Physicians 1, 2
For patients with provoked cerebral venous thrombosis, stop anticoagulation at 3 months if the provoking factor was major and transient, according to the Journal of Thrombosis and Haemostasis 1, 2
For patients with unprovoked cerebral venous thrombosis or persistent risk factors, a minimum of 6 months of anticoagulation is recommended, with reassessment for extended anticoagulation based on bleeding risk stratification, as suggested by the American College of Chest Physicians 1, 2

Patients with low bleeding risk, defined as age <70 years, no previous major bleeding episodes, and no concomitant antiplatelet therapy, may consider extended anticoagulation beyond 12 months, according to Praxis Medical Insights 2
Patients with high bleeding risk, defined as age ≥80 years, previous major bleeding, or severe renal or hepatic impairment, should stop anticoagulation at 6-12 months, as recommended by the Journal of Thrombosis and Haemostasis 2, 3

Mandatory reassessment at 3 months is required to evaluate for extended therapy, and annual reassessment is necessary for all patients on extended anticoagulation, according to the American College of Chest Physicians 1, 2
Imaging at 3-6 months to assess recanalization is recommended, although treatment duration is not determined by clot resolution, as suggested by Praxis Medical Insights 4, 2

Active cancer patients should consider extended anticoagulation regardless of provocation status, preferably with low molecular weight heparin over direct oral anticoagulants or vitamin K antagonists, according to the American College of Chest Physicians 5, 6
Patients with inherited thrombophilia should be treated as unprovoked cerebral venous thrombosis, and the presence of thrombophilia alone does not mandate lifelong anticoagulation but favors extended therapy if bleeding risk is acceptable, as recommended by the Journal of Thrombosis and Haemostasis 3

Every patient with acute cerebral venous thrombosis requires at least 3 months of therapeutic-intensity anticoagulation to prevent thrombus extension and early recurrence, regardless of the presence of intracranial hemorrhage at presentation, as recommended by the American Heart Association, based on evidence from Stroke 7

For patients with active cancer, extended anticoagulation should be considered regardless of whether the cerebral venous thrombosis was provoked, preferably using low molecular weight heparin, according to the American College of Chest Physicians 8
Long-term (indefinite) anticoagulation is indicated for patients with spontaneous cerebral venous thrombosis and a history of recurrent thrombotic events, particularly when combined with inherited thrombophilia, as suggested by the American Heart Association, based on evidence from Stroke 7

Annually for all patients on extended anticoagulation, reassess bleeding risk, medication adherence, drug tolerance, and any changes in health status that might alter the risk-benefit balance, as recommended by the American College of Chest Physicians 9

Do not withhold anticoagulation due to presence of intracranial hemorrhage at cerebral venous thrombosis presentation, as anticoagulation is effective and probably safe even in this context, according to the American Heart Association, based on evidence from Stroke 7
Do not automatically discontinue anticoagulation after imaging shows complete recanalization, and do not use fixed time-limited periods beyond 3 months for unprovoked cerebral venous thrombosis with low-moderate bleeding risk, as recommended by the American College of Chest Physicians 9
Do not treat hormone-associated cerebral venous thrombosis as equivalent to other provoked cerebral venous thrombosis, warranting consideration of 6 months rather than 3 months of therapy, as suggested by the International Society on Thrombosis and Haemostasis 10